(CLOZ) Panagram Bbb-B Clo - Overview
Etf: CLO, Rated, Debt, Fund
Dividends
| Dividend Yield | 8.16% |
| Yield on Cost 5y | 10.44% |
| Yield CAGR 5y | -6.83% |
| Payout Consistency | 94.6% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 4.43% |
| Relative Tail Risk | -16.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.28 |
| Alpha | -0.68 |
| Character TTM | |
|---|---|
| Beta | 0.182 |
| Beta Downside | 0.251 |
| Drawdowns 3y | |
|---|---|
| Max DD | 5.33% |
| CAGR/Max DD | 2.02 |
Description: CLOZ Panagram Bbb-B Clo January 25, 2026
The Panagram Bbb-B CLO ETF (NYSE ARCA:CLOZ) is an actively-managed fund that commits at least 80% of its net assets-plus any investment-purpose borrowings-to collateralized loan obligations (CLOs) carrying ratings from BBB+ down to B- (or equivalent) at purchase. The strategy is non-diversified, meaning a relatively concentrated pool of CLO securities, and it seeks to capture income and capital appreciation from this segment of the leveraged loan market.
As of the most recent quarterly filing (Q3 2025), CLOZ reported approximately $1.2 billion in assets under management with an expense ratio of 0.55%. The portfolio’s weighted-average CLO rating sits at B+, delivering a yield of roughly 5.8% and an average remaining life of 5.2 years. Default rates on the underlying CLO tranches were 1.2% in 2024, well below the historical average of 2.5% for the B-BBB rating band, reflecting a relatively resilient credit environment despite the Federal Reserve’s policy-rate hikes that have compressed loan-to-value spreads. Key sector drivers include the overall health of the leveraged-loan market, corporate refinancing activity, and macro-economic indicators such as GDP growth and credit-cycle positioning, all of which can materially affect CLO performance.
For a deeper quantitative breakdown, you may want to explore the ValueRay platform’s CLO-focused analytics.
What is the price of CLOZ shares?
Over the past week, the price has changed by -0.35%, over one month by +0.43%, over three months by +1.83% and over the past year by +5.48%.
Is CLOZ a buy, sell or hold?
What are the forecasts/targets for the CLOZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 30.1 | 13.3% |
CLOZ Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 766.1m USD (766.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 766.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 766.1m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.59% (E(766.1m)/V(766.1m) * Re(6.59%) + (debt-free company))
Discount Rate = 6.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)